F-FPPRGD PET/CT 用于转移性肾细胞癌患者。
F-FPPRGD PET/CT in patients with metastatic renal cell cancer.
机构信息
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Department of Nuclear Medicine, Kaiser Permanente, Santa Clara, CA, USA.
出版信息
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1518-1523. doi: 10.1007/s00259-019-04295-7. Epub 2019 Mar 8.
PURPOSE
The usefulness of positron emission tomography/computed tomography (PET/CT) using (F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (F-FPPRGD) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.
METHODS
Seven patients with mRCC were enrolled in this prospective study. F-FPPRGD and 2-deoxy-2-(F)fluoro-D-glucose (F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUV) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy.
RESULTS
Sixty lesions in total were detected in this cohort. SUV from F-FPPRGD PET/CT was lower than that from F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUV and T/B from F-FPPRGD PET/CT decreased after starting antiangiogenic therapy (SUV, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUV and T/B were - 29.3 ± 23.6% and - 48.1 ± 28.3%, respectively.
CONCLUSIONS
F-FPPRGD PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.
目的
尚未评估正电子发射断层扫描/计算机断层扫描（PET/CT）使用（F）-2-氟丙酰基标记的聚乙二醇化二聚精氨酸-甘氨酸-天冬氨酸肽[PEG3-E{c（RGDyk）}2]（F-FPPRGD）在转移性肾细胞癌（mRCC）患者中的作用；因此，我们促使进行了这项初步研究。
方法
本前瞻性研究纳入了 7 例 mRCC 患者。对 F-FPPRGD 和 2-脱氧-2-（F）氟-D-葡萄糖（F-FDG）PET/CT 图像进行了逐个病变分析。在开始抗血管生成治疗前后，测量了所有检测到的病变的最大标准化摄取值（SUV）和肿瘤与背景比（T/B）。
结果
本队列共检测到 60 个病灶。F-FPPRGD PET/CT 的 SUV 低于 F-FDG PET/CT（4.4±2.9 与 7.8±5.6，P<0.001）。开始抗血管生成治疗后，F-FPPRGD PET/CT 的 SUV 和 T/B 均降低（SUV，4.2±3.2 与 2.6±1.4，P=0.003；T/B，3.7±3.2 与 1.5±0.8，P<0.001）。SUV 和 T/B 的平均变化分别为-29.3±23.6%和-48.1±28.3%。
结论
F-FPPRGD PET/CT 可能是监测 mRCC 患者抗血管生成治疗早期反应的有用工具。这些初步结果需要在更大的队列中得到证实。
Zotero 插件